IGF-1 LR3
IGF-1 LR3 is a long-acting IGF-1 variant with enhanced anabolic and anti-catabolic activity, and off-label use clusters around muscle growth and hyperplasia, followed by body recomposition and fat loss, with recovery and anti-aging a distant third. In practice, clinicians recommend 100 mcg twice daily at bedtime, cycled four to six weeks, while the twelve community reports are uniformly positive but rarely specify exact dosing. The clearest tradeoff is the complete absence of FDA-approved indications, meaning every human use is off-label or compounded.
Research Evidence
Evidence shape
The evidence for IGF-1 LR3 is strictly animal-only, confined to preclinical mechanistic research with zero registered human trials and no completed studies. The literature maps a single animal-only indication, and the entire available body of work consists of animal models without human subjects or clinical endpoints. That total absence of human data is the load-bearing signal; nothing in the record has advanced to clinical testing.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How IGF-1 LR3 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
- Frequency
- BID
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Clinician protocols dose 100 µg BID subQ (2 sources).
- Frequency
- unspecified
- Timing
- unspecified
- Route
- not specified
- Cycle
- unspecified
Community reports indicate positive outcomes across various use-cases. All 3 reports for muscle growth and hyperplasia were positive, as were all 3 reports for body recomposition and fat loss, and all 2 reports for recovery, repair, and anti-aging. Specific dosing strategies were not consistently reported in threads.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for IGF-1 LR3, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.